Better quality of life with neuropsychological improvement on HAART by Parsons, Thomas D et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Health and Quality of Life Outcomes
Open Access Research
Better quality of life with neuropsychological improvement on 
HAART
Thomas D Parsons*, Alyssa J Braaten†, Colin D Hall† and Kevin R Robertson†
Address: AIDS Neurological Center, University of North Carolina at Chapel Hill, 3114 Bioinformatics Building, Chapel Hill, NC 27599-7025, USA
Email: Thomas D Parsons* - tparsons@neurology.unc.edu; Alyssa J Braaten - braatena@neurology.unc.edu; 
Colin D Hall - hallc@neurology.unc.edu; Kevin R Robertson - kevinr@neurology.unc.edu
* Corresponding author    †Equal contributors
Abstract
Background: Successful highly active antiretroviral therapy (HAART) regimens have resulted in
substantial improvements in the systemic health of HIV infected persons and increased survival
times. Despite increased systemic health, the prevalence of minor HIV-associated cognitive
impairment appears to be rising with increased longevity, and it remains to be seen what functional
outcomes will result from these improvements. Cognitive impairment can dramatically impact
functional ability and day-to-day productivity. We assessed the relationship of quality of life (QOL)
and neuropsychological functioning with successful HAART treatment.
Methods: In a prospective longitudinal study, subjects were evaluated before instituting HAART
(naïve) or before changing HAART regimens because current therapy failed to maintain
suppression of plasma viral load (treatment failure). Subjects underwent detailed
neuropsychological and neurological examinations, as well as psychological evaluation sensitive to
possible confounds. Re-evaluation was performed six months after institution of the new HAART
regimen and/or if plasma viral load indicated treatment failure. At each evaluation, subjects
underwent ultrasensitive HIV RNA quantitative evaluation in both plasma and cerebrospinal fluid.
Results: HAART successes performed better than failures on measures exploring speed of mental
processing (p < .02). HAART failure was significantly associated with increased self-reports of
physical health complaints (p < .01) and substance abuse (p < .01). An interesting trend emerged,
in which HAART failures endorsed greater levels of psychological and cognitive complaints (p =
.06). Analysis between neuropsychological measures and QOL scores revealed significant
correlation between QOL Total and processing speed (p < .05), as well as flexibility (p < .05).
Conclusion:  Our study investigated the relationship between HIV-associated neurocognitive
impairment and quality of life. HAART failures experienced slower psychomotor processing, and
had increased self-reports of physical health complaints and substance abuse. Contrariwise,
HAART successes experienced improved mental processing, demonstrating the impact of
successful treatment on functioning. With increasing life expectancy for those who are HIV
seropositive, it is important to measure cognitive functioning in relation to the actual QOL these
individuals report. The study results have implications for the optimal management of HIV-infected
persons. Specific support or intervention may be beneficial for those who have failed HAART in
order to decrease substance abuse and increase overall physical health.
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Background
Cognitive impairments are known to be associated with
human immunodeficiency virus (HIV) infection. In HIV-
1-associated minor cognitive/motor disorders patient pro-
files are characterized by impaired motor speed and work-
ing memory [1]. Contrariwise, attention, visuo-
constructive abilities, and memory are relatively unim-
paired [2-4]. In HIV-1-associated dementia, behavioral
changes, attention and executive dysfunction, psychomo-
tor slowing, and memory impairment mark patient pro-
files [5]. Although highly active antiretroviral therapy
(HAART) has reduced the incidence of HIV dementia,
HIV-associated cognitive impairment continues to be a
major clinical problem among individuals with advanced
infection [6]. Given the large number of potential path-
ways by which HIV-1 enters brain tissue, persists, and is
activated over time, there is a significant possibility that
HIV-1-associated cognitive-motor disorders may yet
increase as a consequence of increasing resistance to
HAART regimens [7]. Moreover, individuals with HIV-1
infection may experience various neurobehavioral
changes. For example, the debilitating nature of the HIV
disease course has been found to be associated with
increased depression and anxiety, as well as poor quality
of life [8].
Successful HAART regimens have resulted in substantial
improvements in the systemic health of patients with HIV
infection and increased survival times. However, with the
increased longevity of HIV patients, the prevalence of
minor HIV-associated cognitive impairment appears to be
rising among HAART successes. HAART has been shown
to successfully restore immune function and reduce the
effects of opportunistic infection. This restoration of
immune function results in a marked improvement of
HIV-associated diseases and in the reduction of AIDS-
related mortality [9]. However, although HAART
improves physical health, the treatment's effects on neu-
rocognitive and affective symptoms are unclear. Some
studies have shown significant improvement in cognitive
functioning [10,11], while others have shown that some
patients continue to exhibit neurocognitive impairment
even after extended periods of HAART [12,13]. In one
study HIV-associated neurocognitive impairment was
found to be present in nearly one-third of patients on
HAART [14].
In addition to neurocognitive deficits, patients afflicted
with HIV often exhibit affective disorders such as depres-
sion and anxiety. In fact, lower quality of life scores have
been found to be associated with a diagnosis of HIV and
with disease-related symptoms [8,15-17]. Neurocognitive
and affective symptoms appear to be directly related, as
patients exhibiting deficits on neuropsychological testing
also report increased levels of depression and/or anxiety
on self-report measures. This relationship is likely expli-
cated by the fact that cognitively impaired patients are less
likely to employ effective strategies to manage stressors
and in turn to alleviate symptoms of depression and anx-
iety [18]. HAART seems to lessen the affective symptoms
associated with HIV infection [19,20], likely due to the
reduction of physical symptoms associated with the disor-
der.
Quality of life in HIV infection has been shown to be
directly associated with disease stage, disease symptoms,
and cognitive function [14]. Specifically, impairment in
cognitive abilities including fine motor functions, mem-
ory, mental flexibility, concentration, speed of mental
processing, visuospatial abilities, and constructional abil-
ities correlate with reduced quality of life [18]. This find-
ing reinforces the fact that patient's perceptions of their
quality of life is related to their ability to function in soci-
ety and their ability to succeed in activities of daily living
[18]. Further, quality of life has been found to improve
with antiretroviral therapy [21,22]. Significant improve-
ments in the quality of life of symptomatic HIV subjects
have been noted on quality of life measures following
antiretroviral therapy [23]. Thus, a combination of cogni-
tive functioning, affective disturbance, and physical symp-
toms need to be considered when assessing patient's
quality of life and the overall functional outcome of
HAART treatment.
While the effects of HAART have resulted in substantial
improvements in the systemic health of patients with HIV
infection, it remains to be seen what functional outcomes
will result from these improvements. Impairment in cog-
nition can have dramatic impacts on the ability to func-
tion on a day-to-day basis, and to be productive. Initial
studies have demonstrated that neurocognitive improve-
ment occurs in most patients on HAART therapy. In this
study, we assess the relationship of quality of life and neu-
ropsychological functioning with successful HAART treat-
ment.
Methods
The University of North Carolina Institutional Review
Board approved the study, and all participants gave
informed consent for participation. Participants were
enrolled in the study under the following conditions: 1) if
they were about to start HAART; or 2) if, in the opinion of
their infectious disease clinician, their current HAART had
failed and they required a different HAART regimen. There
was no requirement for (or stratification by) presence of
neurologic disease at study entry. Prior to starting or
changing an antiretroviral regimen, a baseline evaluation
was conducted. Participants were reevaluated after 6
months of stable HAART or when, in the opinion of the
treating infectious disease physician, the new regimenHealth and Quality of Life Outcomes 2006, 4:11 http://www.hqlo.com/content/4/1/11
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failed. A neurologist conducted a quantified previously
validated examination particularly sensitive to the
changes found in HIV disease at each evaluation. At each
evaluation, a neuropsychologist conducted detailed psy-
chological and neuropsychological evaluations that have
also been validated as sensitive to the neurocognitive
changes found in HIV disease. At each evaluation, subjects
also underwent ultrasensitive HIV RNA quantitative eval-
uation of both plasma and cerebrospinal fluid.
HIV RNA Load
Viral load assessment was performed through plasma and
cerebrospinal fluid measurements. Within eight hours of
the neurologic evaluation, specimens for viral load and
immune functioning were obtained. Blood and cerebros-
pinal fluid samples were obtained within 3 hours of each
other. Cerebrospinal fluid samples were centrifuged to
remove cells. The Roche Ultrasensitive assay was used to
measure Quantitative HIV-1 RNA load. Prior to viral load
analysis, neurologic and neuropsychological evaluations
were completed in a blinded fashion.
Neurologic examination
The Price and Sidtis [24] AIDS Clinical Trials Group full
neurologic evaluation was used. The neurologic evalua-
tion includes a global assessment of HAD (AIDS dementia
complex stage), which varies from equivocal (0.5) to
severe (3.0) dementia. To increase the sensitivity of the
instrument and to provide domains of functioning, a
quantitative scoring procedure for the neurologic evalua-
tion was implemented, which provides a weighted scoring
approach to the items of the neurologic examination and
yields an overall neurologic total score as well as scores for
cognitive, frontal, pyramidal, extrapyramidal, cranial
nerve, cerebellar, spinal, autonomic, sensory, and periph-
eral domains.
Neuropsychological evaluation
The neuropsychological evaluation included assessment
of the following domains: attention/concentration (2 and
7 test, PASAT), speed of processing (computerized simple
and choice reaction time tasks, digit symbol, trailmaking
A, stroop word), executive functioning (trailmaking B,
stroop colorword, COWA), visuospatial (Rey complex fig-
ure copy), verbal memory (RAVLT), figural memory (Rey
complex figure immediate, delay), gross motor (timed
gait), fine motor (grooved pegboard, finger tapping), and
language (WAIS-R Vocabulary).
Quality of Life
The Neurological Quality of Life questionnaire (Neuro-
QOL) is a self report instrument which assesses eleven
domains: Security, Food, Housing, Financial, Productiv-
ity, Social support, Relationships, Psychological health,
Physical health, Substance abuse, and Cognitive/Neuro-
logical problems. The NeuroQOL questionnaire contains
114 items answered in Likert format. The items are
summed for a total score, with higher scores reflecting bet-
ter quality of life [25,26].
Memorial Sloan Kettering dementia staging
Subsequent to each visit, the Memorial Sloan Kettering
dementia scale was determined for each participant at a
consensus conference, utilizing the neurologic and neu-
ropsychological evaluations, the psychiatric interview,
and the quality of life scale. The Memorial Sloan Kettering
dementia scale is as follows: normal, 0; equivocal (deficits
Table 1: Demographic, virologic, and immunologic variables
Variable Baseline During HAART
Age (y) 41.00 ± 7.77 42.52 ± 7.58
Education (y) 12.00 ± 2.19 12.00 ± 2.15
Plasma HIV level (log copies/mL) 4.87 ± 1.41 3.04 ± 1.84
CSF HIV level (log copies/mL) 3.04 ± 1.47 1.41 ± 1.23
CD4+ cell count (/mm3) 203 ± 183.47 290 ± 242.89
Note: For all analyses N = 59. Data are mean ± SD; CSF = 
cerebrospinal fluid
Table 2: Comparison of success and failure groups on neuropsychological tests
Failure Mean Success Mean t-value p
Attention -0.14 -0.22 0.33 0.74
Speed -0.78 0.09 -2.46 0.02
Flexibility -0.59 -0.61 0.07 0.95
Visual -0.52 -0.40 -0.33 0.74
Verbal -0.52 -0.63 0.45 0.65
Figural -0.23 -0.39 0.78 0.44
Fine Motor -0.54 -0.08 -1.14 0.26
Gross Motor -0.24 0.12 -0.46 0.65
Language -0.21 0.08 -1.22 0.23
Neuropsychology Total Z-
score
-0.52 -0.21 -1.48 0.14
Note: For all analyses N = 59.Health and Quality of Life Outcomes 2006, 4:11 http://www.hqlo.com/content/4/1/11
Page 4 of 7
(page number not for citation purposes)
that do not reach the stage of clear dementia), 0.5; and
dementia, 1-3 (depending on severity) [24].
HAART treatment success and failure
We defined success and failure on HAART by both virolog-
ical and immunological changes. We defined virological
success as a decrease in plasma HIV RNA by 1.5 log cop-
ies/ml and to less than 2.5 log copies/ml. Virological fail-
ures were defined as a decrease of less then 1.5 log copies/
ml or a failure to reduce HIV RNA below 2.5 log copies/
ml. We defined immunological success as an increase in
CD4+ cell count. Immunological failure was defined as
stable or decreased absolute CD4+ cell count.
Data analysis
First, HAART treatment and results on the neuropsycho-
logical battery were compared between groups (HAART
success group and HAART failure group) by using t tests
and an alpha level of 0.05. Next, HAART treatment and
results on the NeuroQol were compared between groups
(HAART success group and HAART failure group) by
using t tests and an alpha level of 0.05. Pearson product-
moment correlation was used to analyze the relationship
between performance on the neurocognitive tasks and
NeuroQol domains.
Results
Eighty-six subjects were evaluated at baseline before treat-
ment with HAART or after failing one treatment regimen
and before instituting a different HAART regimen. Fifty
nine of those then underwent six-month follow-up on sta-
ble HAART. As an ongoing study with continuous enroll-
ment, seven of these participants did not have
opportunity to attend their 6-month followup, as the data
base was cut prior to their 6-month follow up. The drop-
out characteristics of the remaining participants include:
five participants refused lumbar puncture, five had illicit
drug problems, 2 never started HAART, 2 went to prison,
2 had other health related problems, and 2 moved out of
the area. Of those with follow-up (N = 59), the median
age was 42.52 years (SD = 7.58) and a median educational
level of 12 years (SD = 2.15 years). The median CD4+ cell
count was 290 (SD = 242.89), and the median plasma
HIV RNA was 3.04 (SD = 1.84). Demographic, virologic,
and immunologic variables are listed on Table 1.
Forty (68%) subjects were male and 19 were female
(32%). Forty-four (75%) were black, 13 (22%) white, 1
was Asian and 1 was Native American. Forty (68%) had
AIDS by CDC criteria, 7 (12%) were symptomatic and 12
(20%) were asymptomatic.
A quantitative scoring procedure was utilized for the neu-
rological exam, and summary z-scores were calculated for
the neuropsychological battery.
Participants with successful HAART treatment performed
better than failure patients on measures exploring speed
of mental processing (t = -2.46; p < .02). For complete
results comparing Success and Failure groups on neu-
ropsychological measures, see Table 2. The presence of
HAART failure was significantly associated with increased
self-reports of physical health complaints (t = 2.64; p <
.04). Further, there was an interesting trend, in which the
HAART failure group endorsed greater levels of psycho-
logical (t = 1.85; p = .07) and cognitive complaints (t =
1.88; p = .06). For complete results comparing Success
and Failure groups on quality of life measures, see Table
3. Analysis between neuropsychological measures and
quality of life scores revealed significant correlation
between NeuroQOL Total and processing speed (r = -.27;
p < .01), as well as flexibility (r = -.24; p < .03). For com-
plete correlational results see Table 4.
Table 3: Comparison of success and failure groups on NeuroQOL
Failure Mean Success Mean t-value p
Food 4.63 2.78 1.20 0.23
Housing 9.44 4.56 1.66 0.10
Financial 3.91 0.84 1.28 0.20
Product 5.91 4.06 0.62 0.54
Social 6.17 3.47 0.98 0.33
Relation 7.80 6.88 0.27 0.79
Psych 26.78 9.38 1.85 0.07
Physical 18.02 2.50 2.64 0.01
Substance 7.67 0.06 2.80 0.01
Cognitive 12.19 3.59 1.88 0.06
NeuroQOL Total 106.98 41.53 1.82 0.07
Note: For all analyses N = 59. NeuroQOL Total is the total score for the Quality of Life measure.
Mean = 82.63. Standard deviation = 163.47Health and Quality of Life Outcomes 2006, 4:11 http://www.hqlo.com/content/4/1/11
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Discussion
Our study investigated the relationship between HIV-
associated neurocognitive impairment and quality of life.
Our findings revealed that subjects who failed HAART
experienced slower psychomotor processing, and had
increased self-reports of physical health complaints and
substance abuse. On the other hand, those with successful
HAART experienced improved mental processing, demon-
strating the impact of successful treatment on functioning.
Restoration of immune function results in a marked
improvement of HIV-associated diseases and in the reduc-
tion of AIDS-related mortality [9]. With increasing life
expectancy for those who are HIV seropositive, it is impor-
tant to measure cognitive functioning in relation to the
actual quality of life these individuals report. Our results
revealed that participants with successful HAART treat-
ment performed better than failure patients on measures
exploring speed of mental processing, which reflects the
current literature [27]. We also found significant correla-
tions between total quality of life and processing speed, as
well as flexibility.
The presence of HAART failure was significantly associ-
ated with increased self-reports of physical health com-
plaints. These findings reflect current literature, in which
lower quality of life scores have been found to be associ-
ated with a diagnosis of HIV and with disease-related
symptoms [8,15-17]. Further, there was an interesting
trend, in which the HAART failure group endorsed greater
levels of psychological and cognitive complaints. These
findings are consistent with findings that neurocognitive
and affective symptoms appear to be directly related, as
patients exhibiting deficits on neuropsychological testing
also report decreased quality of life. This relationship is
likely explicated by the fact that cognitively impaired
patients are less likely to employ effective strategies to
manage stressors and in turn to alleviate symptoms of
depression and anxiety [18].
Quality of life in HIV infection has been shown to be
directly associated with disease stage, disease symptoms,
and cognitive function [14,28]. Specifically, impairment
in cognitive abilities including fine motor functions,
memory, mental flexibility, concentration, speed of men-
tal processing, visuospatial abilities, and constructional
abilities correlate with reduced health-related quality of
life [18]. Our findings reinforce the fact that patient's per-
ceptions of their quality of life is related to their ability to
function in society and their ability to succeed in activities
of daily living [18]. Thus, a combination of cognitive
functioning, affective disturbance, and physical symp-
toms need to be considered when assessing patient's qual-
ity of life and the overall functional outcome of HAART
treatment.
The study results have implications for the optimal man-
agement of HIV-infected patients' neurocognitive impair-
ment. Our findings support continued investigation of the
presence of neurocognitive impairment in the HAART era.
The association we found with poor quality of life scores
further emphasizes this need. Given these findings, spe-
cific support or intervention may be beneficial for those
who have failed HAART in order to decrease substance
abuse and increase overall physical health. As a subjective
evaluation of persons with HIV related illness, quality of
life provides information relevant to patient care, and
health promoting activities. Specific support or interven-
tion may be beneficial for those who have failed HAART
in order to increase a person's ability to achieve and main-
tain a level of overall functioning necessary to decrease
substance abuse and increase overall physical health. The
identifying of factors that diminish quality of life in HIV
cases is an important step towards improving quality of
life in this population. Further, it allows for screening of
these factors, and in situations where these factors are
present, it aides the clinician in planning and implement-
ing interventions.
Future studies should look at the relations among quality
of life, adherence, substance abuse, neurocognitive scores,
and virological and immunological outcome. Adherence
is a critical component for therapeutic success in HIV
infection and has been shown to be a major determinant
of biological outcome measures in HIV. Substance abuse
has been associated with decreased adherence in several
studies [29,30]. Divergent findings have resulted from
studies investigating adherence and quality of life [31-33].
The relationship between quality of life, adherence, and
neurocognitive sequelae has not been well studied.
Hence, future studies should look at the interrelations
among quality of life, adherence, substance abuse, neuro-
Table 4: Correlations between NeuroQOL total and 
neuropsychological measures
Mean Std.Dv. r(X, Y) P
Attention -0.17 1.11 0.01 Ns
Speed -0.45 1.64 -0.27 0.01
Flexibility -0.60 1.64 -0.24 0.03
Visual -0.48 1.69 0.03 Ns
Verbal -0.56 1.08 0.23 Ns
Figural -0.29 0.89 0.13 Ns
Fine Motor -0.37 1.79 0.08 Ns
Gross Motor -0.11 3.48 0.34 Ns
Language -0.10 1.09 0.74 Ns
Note: For all analyses N = 59. NeuroQOL Total is the total score for 
the Quality of Life measure.
Mean = 82.63. Standard deviation = 163.47Health and Quality of Life Outcomes 2006, 4:11 http://www.hqlo.com/content/4/1/11
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cognitive scores, and virological and immunological out-
come.
Conclusion
In summary, our assessment of quality of life and neu-
ropsychological functioning with HAART treatment
revealed that HAART success was significantly related to
processing speed. HAART failure was significantly associ-
ated with increased physical health complaints, substance
abuse, and a trend toward increased psychological and
cognitive complaints. Significant correlations were found
between quality of life and processing speed, as well as
flexibility. Future studies should include risk and/or sever-
ity factors and look at the relationship between quality of
life, adherence, and neurocognitive sequelae.
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